Stockscreener 앱 받기
219.70
1.69%
-3.77
시간 외 거래:
219.70
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Should Charles River (CRL) Leadership Shift and M&A Push Reshape Its Innovation-Led Growth Strategy? - simplywall.st
Is Charles River Laboratories (CRL) Pricing Reflect Recent Gains And Drug Discovery Contract Momentum - Yahoo Finance
Aug Reactions: What is the next catalyst for Charles River Laboratories International IncJuly 2025 Pullbacks & Short-Term High Return Ideas - baoquankhu1.vn
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Charles River Labs (CRL) and Butterfly Network (BFLY) - The Globe and Mail
Charles River Laboratories stock hits 52-week high at $222.78 By Investing.com - Investing.com Australia
CRL: Strategic divestitures, acquisitions, and biotech demand recovery drive a positive 2026 outlook - TradingView — Track All Markets
Charles River Labs, Boston Scientific announce acquisitions during JPM - The Business Journals
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighStill a Buy? - MarketBeat
Charles River Laboratories stock hits 52-week high at $222.78 - Investing.com
Evercore ISI Group Raises Price Target for Charles River (CRL) t - GuruFocus
Charles River (NYSE: CRL) details 2026 outlook and two acquisitions - Stock Titan
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement - MSN
Charles River to buy Cambodia-based monkey supplier for $510 million - Reuters
Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating - marketscreener.com
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS By Investing.com - Investing.com Nigeria
A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape - simplywall.st
Charles River Laboratories to acquire PathoQuest SAS from SHS Capital By Investing.com - Investing.com Canada
Healthcare Specialist SHS Capital agreed to sell PathoQuest to strategic buyer Charles River Laboratories - TradingView — Track All Markets
Charles River Laboratories Provides Business Updates - PharmiWeb.com
Charles River (CRL) Advances with Strategic Acquisitions and Lea - GuruFocus
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS - Investing.com
Charles River Laboratories International, Inc. $CRL Position Lowered by Iridian Asset Management LLC CT - MarketBeat
Charles River Laboratories (CRL) Stock Analysis: Navigating the Potential in a Challenging Market - DirectorsTalk Interviews
Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO - simplywall.st
Charles River Labs Announces CEO Succession and Leadership Changes - The Globe and Mail
Is Now An Opportune Moment To Examine Charles River Laboratories International, Inc. (NYSE:CRL)? - simplywall.st
Charles River Laboratories (CRL) Announces Leadership Transition - GuruFocus
Charles River Laboratories announces CEO transition, Girshick to succeed Foster - Investing.com Australia
Charles River Labs (CRL) plans CEO succession and new board role for Foster - Stock Titan
What Makes Charles River Laboratories (CRL) an Investment Bet? - MSN
A Look At Charles River Laboratories (CRL) Valuation After Planned CEO Transition And Governance Shift - Yahoo Finance
Why Charles River Laboratories International Inc. stock stays resilientJuly 2025 Rallies & Reliable Trade Execution Plans - ulpravda.ru
Precision Trading with Charles River Laboratories International Inc. (CRL) Risk Zones - Stock Traders Daily
How Charles River Laboratories International Inc. stock compares to growth peersJuly 2025 Final Week & Community Consensus Trade Signals - ulpravda.ru
Will Charles River Laboratories International Inc. stock gain from lower inflationNew Guidance & Daily Chart Pattern Signal Reports - ulpravda.ru
Charles River Labs CEO to retire after more than three decades - NBC Boston
Charles River Laboratories Names Birgit Girshick CEO - citybiz
Charles River CEO Jim Foster to retire in May 2026 after 50-year career - Investing.com India
Can Charles River Laboratories International Inc. stock reach $100 price target2025 Market Outlook & AI Driven Price Predictions - ulpravda.ru
Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes - marketscreener.com
What catalysts could drive Charles River Laboratories International Inc. stock higherMarket Movement Recap & Expert Verified Stock Movement Alerts - ulpravda.ru
Charles River Labs CEO to retire in 2026 after 30+ years at the helm - The Business Journals
Why Charles River Laboratories International Inc. stock is favored by pension funds2025 Technical Patterns & Weekly High Return Forecasts - ulpravda.ru
Charles River CEO Jim Foster to retire in May 2026 after 50-year career By Investing.com - Investing.com South Africa
Charles River Laboratories International, Chair, President, CEO James Foster to Retire - MarketScreener
Charles River Laboratories announces planned retirement of James C. Foster - marketscreener.com
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan - Yahoo Finance
TD Cowen cuts Charles River Labs stock target on revenue pressures - MSN
Portfolio Recap: Is Charles River Laboratories International Inc RV6 stock a top pick for value investorsMarket Risk Analysis & High Accuracy Trade Alerts - moha.gov.vn
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue? - sharewise.com
2.51%
0.74%
자본화:
|
볼륨(24시간):